Since 2004, opportunity cost has been reflected in NICE's appraisal process through the specificatio...
Read moreThis study investigates NICE evaluations of new cancer indications and legacy CDF indications (not p...
Read morePaul Craddy is proud to be presenting at the Global Pharmaceutical Regulatory Affairs Summit in Prag...
Read moreThe Association of British Pharmaceutical Industry has been refused a legal challenge to a cap on th...
Read moreObtaining market access at the right time and at an appropriate price has become more complex for ph...
Read moreIntroduction of a new German Act - Strengthening Pharmaceutical Supply in the Statutory Health Insur...
Read moreA one stop shop for joint advice between EMA, EUnetHTA and health technology assessment bodies - the...
Read moreThis study investigates NICE's evaluation of existing CDF treatments and its potential impact on fun...
Read moreIncluded in this issue is the implications for the UK market regarding Brexit and how the UKs CDF pe...
Read moreMEAs are also known by other names such as risk-sharing agreements, value-added services, and result...
Read more